Anlon Healthcare Ltd
Mon 3/11/2025,15:58:18 | NSE : AHCL
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 128.00
Previous Close
₹ 128.61
Volume
2019862
Mkt Cap ( Rs. Cr)
₹717.49
High
₹ 135.04
Low
₹ 128.00
52 Week High
₹ 147.70
52 Week Low
₹ 90.78
Book Value Per Share
₹ 17.63
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Anlon Healthcare Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
140.19
10932
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
10932
Option Chain
Analyzes market sentiment, predicts Anlon Healthcare Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Anlon Healthcare - Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday, October 16, 2025
-
Anlon Healthcare - Outcome of Board Meeting
-
Anlon Healthcare has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2025
-
Anlon Healthcare - Structural Digital Database
-
Anlon Healthcare - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Anlon Healthcare - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Anlon Healthcare - Trading Window
-
Anlon Healthcare - Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday, September 27, 2025
-
Anlon Healthcare - Outcome of Board Meeting
-
Anlon Healthcare - Board Meeting Intimation for Consider And Approve Proposal For Purchase Of Immovable Property.
-
Anlon Healthcare - Analysts/Institutional Investor Meet/Con. Call Updates
-
Anlon Healthcare - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Anlon Healthcare - Analysts/Institutional Investor Meet/Con. Call Updates
-
Anlon Healthcare - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Anlon Healthcare - Updates
-
Anlon Healthcare - Announcement As Per Regulation 30 Of SEBI LODR, Regulations, 2015 For Development Of New Product.
-
Anlon Healthcare - Price movement
-
Anlon Healthcare - Clarification On Price Movement Regarding Letter Received From L/SURV/ONL/PV/AJ/ 2025-2026 / 3092
-
Anlon Healthcare - Clarification sought from Anlon Healthcare Ltd
-
Anlon Healthcare - Price movement
-
Anlon Healthcare - Analysts/Institutional Investor Meet/Con. Call Updates
-
Anlon Healthcare - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Anlon Healthcare has submitted to BSE the Shareholding Pattern for the Period Ended September 03, 2025
-
Anlon Healthcare Ltd. debuts with 0.00% discount at Rs 91.00
-
Anlon Healthcare - Listing of Equity Shares of Anlon Healthcare Ltd
-
Anlon Healthcare announces launch of initial public offering
Key fundamentals
Evaluate the intrinsic value of Anlon Healthcare Ltd stock
| Name | March-25 | March-24 | March-23 | ||
|---|---|---|---|---|---|
| Assets | 138.7691 | 95.5946 | 73.761 | ||
| Liabilities | 138.7691 | 95.5946 | 73.761 | ||
| Equity | 39.8515 | 16 | 12 | ||
| Gross Profit | 32.2087 | 15.4611 | 12.4148 | ||
| Net Profit | 20.5179 | 9.6571 | 5.82 | ||
| Cash From Operating Activities | -22.5517 | -3.226 | -2.8497 | ||
| NPM(%) | 17.05 | 14.5 | 5.15 | ||
| Revenue | 120.2866 | 66.5837 | 112.8774 | ||
| Expenses | 88.0779 | 51.1226 | 100.4626 | ||
| ROE(%) | 21.89 | 10.3 | 6.2 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Anlon Healthcare Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 883.05 | 3.90 | 80.06 | 73.37 | 301.39 | 0.57 |
| Lotus Eye Hospital and Institute Ltd | 131.17 | 4.91 | 423.13 | 267.34 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 10.00 | -0.40 | 333.33 | 1677.09 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 672.25 | 1.85 | 0.00 | 252.10 | -604.77 | 0.00 |
Company Info
Our Company was originally incorporated as 'Anlon Ventures Private Limited', a private limited company under the erstwhile Companies Act, 1956, pursuant to a certificate of incorporation dated November 19, 2013 issued by the RoC. The name of our Company was changed from 'Anlon Ventures Private Limited' to 'Anlon Healthcare Private Limited' and a fresh certificate of incorporation dated May 27, 2015 was issued by the RoC pursuant to the approval of the Board on May 1, 2015 and the Shareholders on May 5, 2015. Our Company was subsequently converted to a public limited company and the name of our Company was changed from 'Anlon Healthcare Private Limited' to 'Anlon Healthcare Limited' pursruant to the approval of the Board dated July 8, 2024 and Shareholders August 3, 2024 and a fresh certificate of incorporation dated September 2, 2024 was issued by the RoC.Our Company was incorporated in the year 2013 as 'Anlon Ventures Private Limited'. In the year 2015, our Company changed its name to Anlon Healthcare Private Limited and decided to establish its own manufacturing facility for manufacturing of pharmaceutical intermediates and APIs. Following this decision, our company began the process of land procurement, construction, and installation of plant and machinery, which were completed in the year 2017. Year 2017 onwards, we started our trial production of pharma intermediates and APIs.Major Events and Milestones:2013- Incorporated as 'Anlon Ventures Private Limited'2015- Change of name from 'Anlon Ventures Private Limited' to 'Anlon Healthcare Private Limited'.2017- Received ISO 9001:2015 certification2018- Commenced commercial Production of Pharma Intermediate and API2018- Made our first export of our product to South Korea2019- Received Good Manufacturing Practice certification for our Manufacturing Facility- Received accreditation of Foreign Manufacturer from Pharmaceuticals and Medical Devices Agency, Japan2021- Received Good Manufacturing Practice - World Health Organization Certification for our Manufacturing Facility2024- Received approval for Drug Master File from Brazilian Health Regulatory Agency for our API product namely, loxoprofen sodium dihydrate- Conversion of our Company from private limited to public limited and the consequent change of name from 'Anlon Healthcare Private Limited' to 'Anlon Healthcare Limited'.
Our Company was originally incorporated as 'Anlon Ventures Private Limited', a private limited company under the erstwhile Companies Act, 1956, pursuant to a certificate of incorporation dated November 19, 2013 issued by the RoC. The name of our Company was changed from 'Anlon Ventures Private Limited' to 'Anlon Healthcare Private Limited' and a fresh certificate of incorporation dated May 27, 2015 was issued by the RoC pursuant to the approval of the Board on May 1, 2015 and the Shareholders on May 5, 2015. Our Company was subsequently converted to a public limited company and the name of our Company was changed from 'Anlon Healthcare Private Limited' to 'Anlon Healthcare Limited' pursruant to the approval of the Board dated July 8, 2024 and Shareholders August 3, 2024 and a fresh certificate of incorporation dated September 2, 2024 was issued by the RoC.Our Company was incorporated in the year 2013 as 'Anlon Ventures Private Limited'. In the year 2015, our Company changed its name to Anlon Healthcare Private Limited and decided to establish its own manufacturing facility for manufacturing of pharmaceutical intermediates and APIs. Following this decision, our company began the process of land procurement, construction, and installation of plant and machinery, which were completed in the year 2017. Year 2017 onwards, we started our trial production of pharma intermediates and APIs.Major Events and Milestones:2013- Incorporated as 'Anlon Ventures Private Limited'2015- Change of name from 'Anlon Ventures Private Limited' to 'Anlon Healthcare Private Limited'.2017- Received ISO 9001:2015 certification2018- Commenced commercial Production of Pharma Intermediate and API2018- Made our first export of our product to South Korea2019- Received Good Manufacturing Practice certification for our Manufacturing Facility- Received accreditation of Foreign Manufacturer from Pharmaceuticals and Medical Devices Agency, Japan2021- Received Good Manufacturing Practice - World Health Organization Certification for our Manufacturing Facility2024- Received approval for Drug Master File from Brazilian Health Regulatory Agency for our API product namely, loxoprofen sodium dihydrate- Conversion of our Company from private limited to public limited and the consequent change of name from 'Anlon Healthcare Private Limited' to 'Anlon Healthcare Limited'.
Read More
Parent Organisation
Anlon Healthcare Ltd.
Founded
19/11/2013
Managing Director
Mr.Punitkumar R Rasadia
NSE Symbol
AHCLBE
FAQ
The current price of Anlon Healthcare Ltd is ₹ 134.99.
The 52-week high for Anlon Healthcare Ltd is ₹ 135.04 and the 52-week low is ₹ 128.00.
The market capitalization of Anlon Healthcare Ltd is currently ₹ 717.49. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Anlon Healthcare Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Anlon Healthcare Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Anlon Healthcare Ltd shares.
The CEO of Anlon Healthcare Ltd is Mr.Punitkumar R Rasadia, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
